Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefotaxime in transurethral prostatectomy.

K Fujita1, T Murayama

  • 1Department of Urology, National Medical Center Hospital, Tokyo, Japan.

Clinical Therapeutics
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Multifactorial analysis of the pyuria after transurethral prostatectomy].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·1992
Same author

[Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].

Hinyokika kiyo. Acta urologica Japonica·1992
Same author

The activity of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice immunized with type II collagen.

Biochemical medicine and metabolic biology·1992
Same author

Solid-phase anti-CD3 antibody activation and cryopreservation of human tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.

Japanese journal of cancer research : Gann·1992
Same author

Mouse dopamine beta-hydroxylase: primary structure deduced from the cDNA sequence and exon/intron organization of the gene.

Biochemical and biophysical research communications·1992
Same author

Tissue-specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase.

Biochemistry·1992

This study on transurethral prostatectomy patients found that administering cefotaxime before or after surgery did not significantly impact postoperative outcomes or infection rates. Cefotaxime effectively prevented serious infectious complications.

Area of Science:

  • Urology
  • Infectious Diseases
  • Pharmacology

Background:

  • Transurethral prostatectomy (TURP) is a common surgical procedure.
  • Preventing surgical site infections is crucial for patient recovery.
  • Antibiotic prophylaxis is standard practice in many surgical procedures.

Purpose of the Study:

  • To evaluate the efficacy of cefotaxime in preventing infections after transurethral prostatectomy.
  • To compare the outcomes of cefotaxime administration before versus after surgery.

Main Methods:

  • A total of 83 patients undergoing transurethral prostatectomy were included.
  • Patients received 6 gm of cefotaxime in six doses over four days.
  • The first dose was administered either preoperatively (44 patients) or postoperatively (39 patients).

Related Experiment Videos

Main Results:

  • No significant postoperative differences were observed between the pre- and post-surgery cefotaxime administration groups.
  • Pre-existing urinary tract infections (UTIs) were present in 17 patients preoperatively.
  • Only three patients developed UTIs postoperatively, with no serious infectious complications reported in any patient.

Conclusions:

  • Administering cefotaxime perioperatively is effective in preventing serious infectious complications following transurethral prostatectomy.
  • The timing of the first cefotaxime dose (pre- vs. post-surgery) did not appear to influence key postoperative outcomes or infection rates.